Topiglan

Topiglan®

Urology A formulation of alprostadil–synthetic PGE1 in the SEPA transdermal-delivery technology for treating ED. See Erectile dysfunction.
References in periodicals archive ?
MacroChem had previously announced the issuance of a United States patent covering the composition of its Topiglan product for treating male erectile dysfunction.
Such pipeline drugs include Vitaros (alprostadil), Uprima (apomorphine) and Topiglan (alprostadil), amongst others.
MacroChem Corporation (Nasdaq:MCHM), a drug development company specializing in transdermal (through-the-skin) drugs, recently announced that the February issue of UROLOGY, a respected peer-reviewed specialty journal, carries a paper detailing a successful Phase 2 study demonstrating the safety and efficacy of Topiglan, MacroChem's topical drug for erectile dysfunction.
MacroChem hopes Topiglan will become the first-line therapy for all ED patients, including those who can't take Viagra or Viagra-class drugs.
A topical gel called Topiglan produces a powerful erection with just a drop on the head of the penis.
That study did not meet clinical endpoints, as previously announced, and the company has decided not to conduct further clinical trials of Topiglan at this time.
April 14 /PRNewswire/ -- MacroChem Corporation announced today that preliminary data from its Phase 2 pharmacodynamic study of Topiglan(R), a topical cream for erectile dysfunction, demonstrate that Topiglan did not meet the study's primary clinical endpoints.
MacroChem Corporation (Nasdaq: MCHM) announced today that preliminary data from its Phase 2 pharmacodynamic study of Topiglan(R), a topical cream for erectile dysfunction, demonstrate that Topiglan did not meet the study's primary clinical endpoints.